Drug interactions in children rarely announce themselves. A child on antimalarial treatment gets started on a second medicine for something unrelated, and before anyone notices, there is a combination in play that no one flags until side effects show up. Children are not just small adults. Their livers and kidneys are still maturing, off-label prescribing is common, and so much of paediatric dosing runs on weight alone, all of which leaves them more exposed to drug-drug interactions than most people realise (1).
This is exactly the gap a Drug-Drug Interaction Checker is built for: catching a risky combination before it ever reaches the child.
What actually counts as a drug-drug interaction in a child?
It is when one medicine changes how another is absorbed, broken down, or cleared from the body, or when two drugs, each working on their own, combine to produce an effect neither would cause alone. In children, this usually plays out one of two ways: pharmacokinetically, most often through the cytochrome P450 enzyme system, or pharmacodynamically, where both drugs act on the same physiological pathway (2).
Why are children more vulnerable to drug interactions than adults?
Mostly because their enzyme systems have not finished developing. On top of that, children are often prescribed several medicines at once for overlapping infections, and a good deal of paediatric prescribing happens off-label without much interaction data behind it. Critical illness, polypharmacy, and impaired liver or kidney function each raise the risk independently, and children in intensive care often carry more than one of these factors at the same time (2,3).
A PubMed-indexed study across 52 United States children’s hospitals found that 2.0 percent of hospitalisations involved exposure to a clinically significant drug pairing, roughly 35 exposures per 1,000 patient-days (3). A separate paediatric intensive care review found that around 70 percent of the interactions it classed as clinically relevant were also high severity, so the ones that do occur are rarely minor (4).
Which drug interactions carry the most risk in children?
A small number of mechanisms and drug classes account for most of the interactions that actually matter clinically.
- Enzyme-inducing antiepileptics and anti-tuberculosis drugs (rifampicin especially) lowering the blood levels of co-administered drugs, including antiretrovirals
- Azole antifungals and macrolide antibiotics inhibiting CYP3A4, which raises the levels of other drugs metabolised through the same pathway, such as calcium channel blockers
- Antiretroviral therapy combined with antimalarial treatment, particularly artemisinin-based combinations, in children being treated for both HIV and malaria
- Nephrotoxic combinations, such as aminoglycosides alongside other renally cleared drugs, especially in a dehydrated or septic child
- QT-prolonging combinations, including certain antimalarials paired with macrolides
Which drug interactions matter most in Nigerian paediatric practice?
In Nigerian children living with HIV, the interaction that comes up most often is between antiretroviral therapy and artemisinin-based combination therapy (ACT), the first-line antimalarial used in Nigeria. Rifampicin, used to treat tuberculosis, has also been identified as the drug most often involved in a contraindicated combination (5). A PubMed-indexed review of HIV-infected children at a Lagos teaching hospital clinic found clinically significant interactions in most of the cases reviewed once antimalarial co-prescribing was factored in, though that proportion dropped sharply once presumptive treatment (started without lab confirmation) was excluded (5).
The practical lesson for Nigerian clinics is simple: confirm malaria with blood microscopy or a rapid diagnostic test before treating a child already on antiretroviral therapy, rather than treating presumptively. And if a child is starting tuberculosis treatment alongside antiretrovirals, check the regimen for a rifampicin interaction before the first dose goes out (5).
How can clinicians screen for drug interactions before prescribing?
Every new medicine added to a child’s regimen should be checked against everything else they are already taking, not assumed safe just because each drug looks familiar on its own. Running the full medicine list through Medituri’s Drug-Drug Interaction Checker before prescribing helps catch combinations that are easy to miss when medicines get reviewed one at a time instead of as a whole regimen.
What monitoring should follow a high-risk paediatric drug combination?
- Confirm the indication for each drug on its own, and stop anything the child no longer needs
- Check the full medicine list, including over-the-counter and herbal products, against an interaction database before adding anything new
- Step up monitoring (renal function, ECG, or drug levels, depending on the pair) when an interacting combination cannot be avoided
- Document the interaction risk in the chart so the next prescriber is not caught off guard
- Counsel caregivers on the warning signs specific to that interaction, not just the individual drugs
Which drug classes carry the highest interaction risk in children?
| Drug class | Mechanism of concern | Practical management |
|---|---|---|
| Rifampicin (anti-TB) | Strong CYP3A4 inducer; lowers levels of co-prescribed drugs, including antiretrovirals (5) | Review and adjust the ART regimen before starting TB treatment |
| Artemisinin-based combinations | Interacts with ART; risk climbs with presumptive (unconfirmed) malaria treatment (5) | Confirm malaria by microscopy or RDT before treating a child on ART |
| Azole antifungals / macrolides | CYP3A4 inhibition; raises levels of drugs sharing the same pathway (2,4) | Check interaction status before co-prescribing; monitor for toxicity |
| Aminoglycosides + other nephrotoxic drugs | Additive renal toxicity, worsened by dehydration or sepsis (2) | Avoid combining where possible; monitor renal function closely |
So what is the key takeaway on paediatric drug interactions?
Most of the serious interactions in children trace back to a small, recognisable set of drug classes, and most are preventable with a routine check at the point of prescribing rather than relying on memory. In a Nigerian paediatric setting, that check matters most whenever antiretroviral therapy, antimalarials, or anti-tuberculosis drugs are being prescribed together.
Where can clinicians check a regimen quickly?
Medituri’s Drug-Drug Interaction Checker screens a child’s full medicine list in seconds, flagging these and other clinically significant combinations before they reach the prescription pad.
Frequently Asked Questions
What is the most common drug interaction in children with HIV in Nigeria?
The most frequently reported interaction in Nigerian children living with HIV is between antiretroviral therapy and artemisinin-based antimalarials, often driven by presumptive malaria treatment without lab confirmation. Rifampicin, used for tuberculosis, has also been identified as the drug most often involved in a contraindicated combination (5).
Why are children more at risk of drug interactions than adults?
Children have immature liver and kidney function, are often prescribed medicines off-label, and frequently need multiple drugs for overlapping infections, all of which raise the risk of a drug interaction. Critical illness and polypharmacy make it more likely a significant interaction goes unnoticed.
Should malaria always be confirmed before treating a child on antiretroviral therapy?
Yes. Treating malaria presumptively in a child already on antiretroviral therapy increases exposure to a known interacting combination. Confirming malaria with blood microscopy or a rapid diagnostic test first avoids that risk when the child does not actually have malaria (5).
Can two safe individual drugs still be dangerous together in a child?
Yes. A drug interaction happens because of how two medicines affect each other’s metabolism or combine in their effect, not because either drug is unsafe on its own. That is why checking the full medicine list together, rather than reviewing each drug in isolation, matters.
How severe are paediatric drug interactions when they do occur?
Most potential interactions identified in children do not lead to real clinical harm, but when one does turn out to be clinically relevant, it is often serious. One paediatric intensive care study found around 70 percent of the clinically relevant interactions it identified were high severity (4).
What is the single most effective step to prevent a paediatric drug interaction?
Running every new medicine against the child’s complete current drug list before prescribing, rather than assessing each addition on its own, catches most preventable interactions. A digital interaction checker makes this step fast enough to use routinely, not just in complex cases.
References
1. Evaluation of potential drug-drug interactions in a pediatric population. PMC. 2020.
2. Feinstein JA, et al. The incidence and clinical relevance of drug interactions in pediatrics. PMC. 2015.
3. Prevalence of Clinically Significant Drug-Drug Interactions Across US Children’s Hospitals. PMC. 2021.
4. Clinical significance of potential drug-drug interactions in a pediatric intensive care unit: a single-center retrospective study. PMC. 2021.
5. Oshikoya KA, et al. Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria. HIV/AIDS (Auckl). 2014.
